Production (Stage)
Galectin Therapeutics Inc.
GALT
$1.32
-$0.02-1.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.41M | 1.32M | 1.47M | 1.48M | 1.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.90M | 12.43M | 9.07M | 11.29M | 9.65M |
| Operating Income | -7.90M | -12.43M | -9.07M | -11.29M | -9.65M |
| Income Before Tax | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M |
| EBIT | -7.90M | -12.43M | -9.07M | -11.29M | -9.65M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.15 | -0.19 | -0.18 | -0.20 | -0.19 |
| Normalized Basic EPS | -0.10 | -0.12 | -0.11 | -0.12 | -0.12 |
| EPS Diluted | -0.15 | -0.19 | -0.18 | -0.20 | -0.19 |
| Normalized Diluted EPS | -0.10 | -0.12 | -0.11 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 63.20M | 62.75M | 62.28M | 62.23M | 61.98M |
| Average Diluted Shares Outstanding | 63.20M | 62.75M | 62.28M | 62.23M | 61.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |